| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. |
| Indication |
For the management of increased muscle tone associated with spasticity |
| Pharmacology |
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Half Life |
2.5 hours |
| Protein Binding |
30% |
| Elimination |
Approximately 95% of an administered dose is metabolized. |
| Distribution |
* 2.4 L/kg |
| External Links |
|